| Psoriasis vulgaris
Bryhali vs Duobrii
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Bryhali vs Duobrii with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDuobrii has a higher rate of injection site reactions vs Bryhali based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Duobrii but not Bryhali, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bryhali
Duobrii
At A Glance
Topical
Daily
Topical corticosteroid
Topical
Once daily
Corticosteroid/retinoid combination
Indications
- Psoriasis vulgaris
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris Apply a thin layer to affected areas once daily; do not exceed 8 weeks of treatment or approximately 50 g per week; discontinue when control is achieved; avoid occlusive dressings unless directed, and do not use on face, groin, or axillae.
Psoriasis vulgaris Apply a thin layer once daily to affected areas, rubbing in gently; total dosage should not exceed approximately 50 g per week; avoid application on the face, groin, or axillae; do not use with occlusive dressings unless directed by a physician; discontinue when control is achieved.
Contraindications
—
- Pregnancy
Adverse Reactions
Most common (>=1%) Upper respiratory tract infection, application site dermatitis, hyperglycemia
Most common (>=1%) contact dermatitis, application site pain, folliculitis, skin atrophy, excoriation, rash, skin abrasion, skin exfoliation
Pharmacology
Topical corticosteroid; corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation, though the precise mechanism of action in plaque psoriasis is unknown.
Combination of halobetasol propionate, a synthetic corticosteroid that modulates cellular signaling, immune function, and inflammation, and tazarotene, a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds RAR-beta and RAR-gamma receptors to modify gene expression; precise mechanisms in plaque psoriasis are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bryhali
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (6/12) · Qty limit (9/12)
Duobrii
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Bryhali
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Duobrii
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Bryhali
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Duobrii
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bryhali.
No savings programs available for Duobrii.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BryhaliView full Bryhali profile
DuobriiView full Duobrii profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.